Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
New York Citys health insurer stopped covering GLP-1 drugs for city employees in 2025 while Bostons leaders are considering limiting such coverage for city employees because of an insurance rate hike largely driven by the GLP-1 drug cost
When it comes to people with obesity and without diabetes, the 2025 AACE guidelines recommend semaglutide and tirzepatide as first line over other drug classes for a variety of conditions, including those with prediabetes, type 2 diabetes, osteoarthritis, kidney disease, heart failure, fatty liver, cardiovascular protection, and sleep apnea
Semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) and is HSA/FSA eligible
Gallbladder problems, dehydration-related kidney issues, and serious allergic reactions are also warning areas discussed in labeling
The most cited independent labs include those using standard USP or ISO-accredited HPLC methods
Seek emergency care for severe or persistent abdominal pain, especially pain that moves toward the back, as it could mean pancreatitis
